Press Releases

Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi’s existing cash and Cara’s...

Piper Sandler & Co. to act as financial advisor STAMFORD, Conn. , July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives....

– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn. , June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a development-stage...

Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 STAMFORD, Conn. , May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new...

STAMFORD, Conn. , May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial...

STAMFORD, Conn. , April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner , President and Chief...

STAMFORD, Conn. , March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader...

–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash...

STAMFORD, Conn. , Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024 , at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a...

– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ended 2023 with approximately $101 million in cash;...